Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Texas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Texas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Texas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Diman Lamichhane (NPI 1700067360)

Field	Value
Entity Type	Individual
Organization	Diman Lamichhane
Address	1327 Troup Hwy
City	Tyler
State	TX
ZIP	75701
Taxonomy	Rheumatology Physician
NPI Enumerated	November 23, 2007

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

DIMAN LAMICHHANE has generated $2.1M in lifetime Medicare revenue with no Medicaid billing on file, indicating an effectively single-payer footprint concentrated in Medicare services and infused/infusion-related treatments rather than a mixed Medicaid–Medicare practice. The absence of any Medicaid codes suggests the provider’s patient mix and billing operations are focused on fee-for-service Medicare beneficiaries and infused biologic therapies typically reimbursed under Medicare Part B.

Revenue concentration is high: the precomputed top three Medicare codes by revenue account for 58.4% of total Medicare revenue, showing the practice depends heavily on a small set of high-cost injectable biologic drugs. Those top codes — J0129, J3262, and J1602 — together drive more than half of Medicare receipts, indicating business risk if utilization or coverage for these agents changes.

Service-line profile: the top codes (J0129, J3262, J1602, J1745, J9312) are predominantly high-cost biologic infusions and injections (abatacept, tocilizumab, golimumab, infliximab, rituximab), signaling that the provider’s operations are infusion-centric and likely include onsite administration and associated chemotherapy/infusion support services. Supporting CPT activity such as 96413, 96415, and infusion add-ons (96375, 96365) reinforces an operational model that delivers intravenous/subcutaneous biologic and chemotherapeutic administrations rather than primarily office-based procedure-only care.

Competitive standing on Medicare is mixed: the provider ranks in the mid-to-high national percentiles for several large biologic codes (for example, J0129 at the 84th percentile, J3262 at the 83th percentile, and J1602 at the 84th percentile), indicating typical-to-strong national volumes for these therapies, while J1745 (infliximab) is at the 95th percentile and described as notably above typical national volume, marking a particular strength or specialty in administering that agent relative to peers. Conversely, some infusion/oncology administration codes like 96413 and 96415 also show notably above typical national volumes (98th percentile), suggesting the provider is comparatively active in chemotherapy/infusion administration among national peers.

Risk and service diversification: although a broad list of CPT/HCPCS codes appears (office E/M codes 99214/99213, arthrocentesis codes 20611/20604, imaging guidance 76942), these contribute relatively small shares of revenue compared with biologic drug codes (for example, 99214 accounts for $48.1K or 2.3% of Medicare revenue). This pattern implies the practice supplements its infusion business with routine rheumatology office visits and procedure work but relies primarily on high-revenue drug administrations for its financial base.

Tenure and experience: the provider’s NPI was enumerated on 2007-11-23 (~19 years ago), indicating long-standing enrollment in Medicare and an established billing history. That tenure, combined with high-volume biologic administration rankings for several agents, suggests the provider has built sustained operational capacity for infusion services over nearly two decades.

Statistical outliers and notable volumes: several codes are explicitly flagged as above-typical in national volume — J1745 (95th percentile, notably above typical) and infusion administration codes 96413 and 96415 (98th percentile, notably above typical) — highlighting outlier-level activity in infliximab use and infusion delivery compared with national peers. Other commonly used biologics (J0129, J3262, J1602) are described as typical/unremarkable volume in their respective percentiles, which portrays a practice that is highly active on a few specific agents while maintaining routine levels on others.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

23 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	16,950	$30	$542.4K
J3262	Injection, tocilizumab, 1 mg	76,490	$10	$382.4K
J1602	Injection, golimumab, 1 mg, for intravenous use	28,880	$10	$317.7K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	11,540	$30	$288.4K
J9312	Injection, rituximab, 10 mg	3,750	$60	$217.5K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	34,400	$1	$137.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	800	$100	$77.2K
J0897	Injection, denosumab, 1 mg	4,020	$20	$72.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	560	$90	$48.1K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	220	$50	$11.6K

Showing 1–10 of 23

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 23 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Texas Distribution

Diman Lamichhane — 4 of 23 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Texas

Full comparison — all codes billed, vs. state median

23 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	3	100	9,950	$30	$393.1K
J0717	2	90	56,000	$1	$272.5K
J9312	4	20	3,830	$60	$248.5K
J3262	2	40	31,800	$1	$212K
J1602	3	90	14,850	$10	$184.1K
J1745	1	110	2,660	$30	$90.6K
J0897	22	650	2,580	$20	$79.2K
96413	2	810	150	$100	$19.7K
99214	194	32,500	110	$80	$17.6K
96401	1	480	100	$50	$9.9K

Showing 1–10 of 23

Related Providers

Other providers that share a Tax Identification Number (TIN) with Diman Lamichhane, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Oregon Healthcare Resources, LLC	OR	Multi-Specialty Clinic/Center	$0	$8.8M
William Hinz	OR	Rheumatology Physician	$1.2M	$0
William P Maier Md PC	OR	Rheumatology Physician	$0	$953.9K
William Maier	OR	Rheumatology Physician	$857.6K	$0
Blake Sampson	UT	Dermatology Physician	$592.7K	$0
Dane Dougherty	OR	Rheumatology Physician	$505.9K	$0
Steven Wilhelm	WA	Diagnostic Radiology Physician	$439.1K	$0
Todd Knapp	OR	MOHS-Micrographic Surgery Physician	$369.3K	$0
Norbert Yee	WA	Diagnostic Radiology Physician	$320.9K	$0
Gregory Kujawski	WA	Diagnostic Radiology Physician	$284.9K	$0

Nearby Providers

Other providers in the same ZIP code as Diman Lamichhane, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mother Frances Hospital Regional Health Care Center	TX	General Acute Care Hospital	$0	$32.9M
Premier Kids Care Inc	TX	Community/Retail Pharmacy	$0	$28.2M
Pediatric Home Healthcare, LLC	TX	Home Health Agency	$0	$23.7M
Thomas Bochow	TX	Ophthalmology Physician	$3.6M	$0
Wendy Prewett	TX	Acute Care Nurse Practitioner	$2.9M	$0
Heaton Laser And Surgery Center L L C	TX	Ambulatory Surgical Clinic/Center	$2.7M	$113K
Angela Sutherland	TX	Nurse Practitioner	$2.3M	$0
Trincare Inc	TX	Clinical Medical Laboratory	$539.4K	$1.5M
Speed Of Light Xray, LLC	TX	Portable X-ray and/or Other Portable Diagnostic Imaging Supplier	$1.3M	$529.8K
Thomas Buzbee	TX	Internal Medicine Physician	$1.5M	$0

Diman Lamichhane — Billing Profile & Reimbursement Data

Sign up for Diman Lamichhane — Billing Profile & Reimbursement Data policy alerts

Diman Lamichhane — Billing Profile & Reimbursement Data

Sign up for Diman Lamichhane — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References